Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety
CADTH
Record ID 32014000192
English
Authors' recommendations:
Rasburicase was found to lower uric acid levels in adult cancer patients who had, or were at risk for developing, hyperuricemia or tumour lysis syndrome (TLS). Rasburicase was found to be well tolerated in adult cancer patients, with a low rate of adverse events, renal failure, or need for hemodialysis. No evidence on the cost effectiveness of rasburicase compared with allopurinol or hydration for adults with acute TLS was identified.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/apr-2013/RC0441%20Rasburicase%20for%20Adults%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Tumor Lysis Syndrome
- Adult
- Cost-Benefit Analysis
- Urate Oxidase
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.